Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other Non-Current Assets (2023 - 2025)

CG Oncology filings provide 3 years of Other Non-Current Assets readings, the most recent being $1.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 1685.11% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 1685.11% increase, with the full-year FY2025 number at $1.7 million, up 1685.11% from a year prior.
  • Other Non-Current Assets hit $1.7 million in Q4 2025 for CG Oncology, up from $114000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.7 million in Q4 2023 to a low of $53000.0 in Q1 2024.
  • Median Other Non-Current Assets over the past 3 years was $114000.0 (2025), compared with a mean of $861111.1.
  • Biggest five-year swings in Other Non-Current Assets: crashed 97.99% in 2024 and later skyrocketed 1685.11% in 2025.
  • CG Oncology's Other Non-Current Assets stood at $4.7 million in 2023, then crashed by 97.99% to $94000.0 in 2024, then skyrocketed by 1685.11% to $1.7 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.7 million (Q4 2025), $114000.0 (Q3 2025), and $522000.0 (Q2 2025) per Business Quant data.